| 0.238 -0.002 (-0.79%) | 12-08 15:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.44  |
1-year : | 0.56 |
| Resists | First : | 0.38 |
Second : | 0.48 |
| Pivot price | 0.3 |
|||
| Supports | First : | 0.21 |
Second : | 0.18 |
| MAs | MA(5) : | 0.25 |
MA(20) : | 0.32 |
| MA(100) : | 0.57 |
MA(250) : | 1.51 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.9  |
D(3) : | 9.8 |
| RSI | RSI(14): 31.1 |
|||
| 52-week | High : | 8 | Low : | 0.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATNF ] has closed above bottom band by 12.9%. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.25 - 0.25 | 0.25 - 0.25 |
| Low: | 0.22 - 0.22 | 0.22 - 0.22 |
| Close: | 0.23 - 0.24 | 0.24 - 0.24 |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Mon, 04 Dec 2023
180 Life Sciences engages financial advisor to explore strategic alternatives - Seeking Alpha
Mon, 04 Dec 2023
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives - Yahoo Finance
Wed, 29 Nov 2023
180 Life Sciences : Material Agreement - Form 8-K -November 29, 2023 at 08:13 am EST - Marketscreener.com
Wed, 29 Nov 2023
Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - 180 Life Scienc - Benzinga
Sun, 12 Nov 2023
Certain Warrants of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023. - Marketscreener.com
Wed, 09 Aug 2023
180 Life Sciences (NASDAQ: ATNF) up 75% - that cannabis delusion again - Dhaka Tribune
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 160 (K) |
| Shares Short P.Month | 104 (K) |
| EPS | -14.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56.2 % |
| Return on Equity (ttm) | -312.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | -11.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|